ReviewFrontiers in pharmacology2025
Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Long-Term Follow-Up of Levetiracetam Monotherapy Versus Add-On Therapy in Pediatric Epilepsy.Children (Basel, Switzerland) · 2026Article
- What guidance is available for people with epilepsy wanting to participate in sport and exercise? A narrative review.JSAMS plus · 2026Review
- Antipsychotic use among paediatric patients living with epilepsy in Uganda.Scientific reports · 2026Article
- Natural Products in Epilepsy Treatment: From Traditional Medicine Towards Computational Drug Discovery.Current issues in molecular biology · 2026Review
- Treatment patterns and adverse events of antiseizure medications among adult patients with epilepsy: a single centre observational cross-sectional study in Northern Sri Lanka.BMC neurology · 2026Observational
- Burden and Determinants of Adverse Effects from Antiseizure Medications: Insights from Saudi Cohort.Medicina (Kaunas, Lithuania) · 2026Article
- Patient Median-Based Quality Control in Lamotrigine Therapeutic Drug Monitoring: A 15-Year Retrospective Study.Pharmaceutics · 2026Article
- "Homicide and Zonisamide": a review of the literature and illustrative case report on second and third generation antiseizure medications and psychiatric effects.Frontiers in psychiatry · 2026Article
- Narcolepsy-like presentations in intellectual disability with comorbid epilepsy and obstructive sleep apnea: a case-based diagnostic analysis and literature-informed discussion.Frontiers in psychiatry · 2026Article
- From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders.International journal of molecular sciences · 2025Review
- Real-world disproportionality analysis of sleep disturbances associated with antiseizure medications in epilepsy: a pharmacovigilance study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a chronic and debilitating neurological disorder characterized by the occurrence of spontaneous and recurrent seizures. Despite the availability of several antiseizure medications (ASMs), people with epilepsy often experience drug resistance and adverse effects. This narrative review provides an overview of the main adverse drug reactions (ADR) caused by ASMs, including neurological, metabolic, skin reactions and drug failure, and of the underlying molecular mechanisms. Given the critical contribution of pharmacogenomics and drug-drug interactions to the occurrence of some ADRs, we provide examples of the role of major allelic variations identified in genes encoding for molecules involved in the pharmacokinetics, pharmacodynamics and immune system and emphasize the activity of ASMs as inhibitors or inducers of metabolic enzymes. Improved knowledge of the benefit-risk profile of drugs, also through enhanced pharmacovigilance activity and following guidelines recommendations, could implement patients care avoiding ADRs and favoring a beneficial personalized medicine particularly in vulnerable patients as children, elderly people and pregnant women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.